Reagenzien und Instrumente für die Immunologie Zellbiologie und Molekularbiologie
 
> Rapamycin [53123-88-9]

Rapamycin [53123-88-9]

Drucken Drucken
Melden Sie sich an

Katalog-Nummer HY-10219-10mg

Size : 10mg

Marke : MedChemExpress

Contact local distributor :


Telefonnummer : +1 850 650 7790

Rapamycine (Sirolimus; AY 22989) est un inhibiteur puissant et spécifique de mTOR avec un IC50 de 0,1 nM dans les cellules HEK293. Rapamycine se lie au FKBP12 et agit spécifiquement comme un inhibiteur allostérique de mTORC1. Rapamycine est un activateur de l'autophagie, un immunosuppresseur.

Rapamycin (Sirolimus; AY 22989) ist ein potenter und spezifischer mTOR-Inhibitor mit einem IC50 von 0,1 nM in HEK293-Zellen. Rapamycin bindet an FKBP12 und wirkt spezifisch als allosterischer Inhibitor von mTORC1. Rapamycin ist ein Autophagie-Aktivator, ein Immunsuppressivum.

Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Rapamycin Chemische Struktur

Rapamycin Chemische Struktur

CAS. Nr. : 53123-88-9

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Rapamycin Related Antibodies

WB
IHC
IF
    Rapamycin (50 nM; 24 h) efficiently inhibits the Cobalt-induced hyperphosphorylation of Tau in Ser262 and Thr181, when in H4 cells.
    Rapamycin (100 nM; 24 h) increases PRRSV replication in Marc-145 cells.
    Rapamycin (2.5 mM; 24 h) ignificantly reverses the PCK1-sh-induced decreased expression of LC3B-II in SW480-sh cells.
    Immunofluorescence staining of p62 is conducted in HSC-T6 cells. G-Rg3 pretreatment with 16 μM and Ra are conducted with 100 or 200 nM.
    Western blot and quantification of P-AKT (Ser473) and P-S6RP in the liver, heart and muscle, respectively, of PIK3CAWT and PIK3CACAGG-CreER mice treated with vehicle or Rapamycin directly after Cre induction.
    Evident LC3 turnover and increased level of Atg5 are found upon Rapamycin treatment, which indicate significant autophagy activation.
    H1975 cells are pretreated with Rapamycin (100 nM) for 1 h and then cells are exposed to IFN-γ (100 U/mL). Phosphorylation of AKT, S6, 4E-BP1 are analyzed by western blotting.
    L02 cells exposed to PA (200 μM) with different concentrations of Rapamycin (Rapa) or Chloroquine (CQ) for 24 h. Palmitate (PA) induced higher protein expression of LC3 II/I and p62 compared with control as indicated by western blot.
    Raw264.7 macrophages treated without or with Rapamycin (1 μΜ) or Chloroquine (20 μΜ) for 48 h. Western blot shows the protein expression levels of Atg5, Beclin1, LC3, and p62/SQSMT1.
    Effect of treatment with Rapamycin, trehalose, or their combination on autophagy activity measured by quantified immunoreactivity of LC3-II in the s. nigra. MPTP is administered at the dose of 20 mg/kg (i.p., daily) for 4 days to induce PD-like pathology.
    Effect of treatment with Rapamycin, trehalose, or their combination on tyrosine hydroxylase (TH) expression in the striatum in MPTP-induced mouse model of Parkinson’s disease.
    The mTOR inhibitor Rapamycin augments the autophagy induced by GEM. (A, B) Beclin-1 and LC3B expression is analyzed by western blot after treatment of the cells with GEM (5 μM) and Rapamycin (0, 1, and 2.5 μM) for 48 (A) or 72 (B) h.
    C6/36 cells are treated with 3-MA, Rapa or CQ for 36 h, 6 h and 36 h, respectively and then subjected to MDC staining. Mock and DMSO treated C6/36 cells are used as controls.
    C6/36 cells are treated with 3-MA, Rapa or CQ for 36 h, 6 h and 36 h, respectively. For Rapa plus CQ treatment, C6/36 cells are treated with CQ for 30 h then treated with Rapa for 6 h. Mock and DMSO treated C6/36 cells are used as controls. After the treatment, the levels of AaAtg8-I and AaAtg8-II are analysed by immunoblotting using antibody against AaAtg8.
    Western blotting shows that Rapamycin treatment downregulates p-mTOR protein levels in infected and uninfected corneal tissues compared to the vehicle group.
    Western blot analysis of AKT, p-Akt, mTOR, p-mTOR, FOXO1 and p-FOXO1 expression in U-87 MG cells after treatment with LY294002 (20 μM), Rapamycin (50 nM) or NAC (5 mM) with or without Xihuang pill (XHP).
    Cells are pretreated with 5 mM 3-MA or 2 μM for 1 h and then exposed to 40 μM EPA and 10 μM Rp for 48 h. Cell extracts are prepared and subjected to western blot analysis.
    Cells are treated with Rapamycin (Rp; 10 μM)+Eicosapentaenoic acid (EPA; 40 μM) with or without Chloroquine (CQ; 5 μM) for 48 h. Cell extracts are prepared and subjected to western blot analysis.
    Immunoblot analysis of KRAS protein levels in parental (P) and resistant derivatives (R1 and R2) following 4 h treatment with the corresponding inhibitors Rapamycin, AZD2014, MLN0128, BEZ235 and 4EGI-1. Images are cropped for clarity from the same exposure of the same membrane.
    Phosphorylation of SMAD1/5/8 and SMAD2/3 in FOP-iMSCs. Serum-starved FOP-iMSCs are pretreated with 10 nM Rapamycin (Rapa), 1 μM DMH1, or 1 μM SB-431542 for 1 hour.
    FTY720 reverses activation of autophagy induced by mTOR inhibitor, rapamycin. The impact of FTY720 and Rapamycin on the expression of Beclin1 and LC3 is evaluated by western blotting. Results are representative of 4 independent experiments.
    RAW264.7 cells transfected with miR-144-3p control or miR-144-3p mimic in full medium with or without 50μg/mL Rapamycin or 0.1% DMSO. 50 μg of total cell extracts are analyzed by Western blotting with a mouse anti-SQSTM1/p62 antibody. The p62 levels are detected by Western-blot (upper). Quantitative analysis of the p62 band normalized to β-actin is shown (lower).
    Inhibition of SREBPs processing by AHI is dependent on LKB-1/AMPK/mTOR pathway. (A) HepG2 cells are incubated with or without MHY1485 or Rapamycin for 1 h, the cells are switched to medium D in the presence of vehicle, or AHI. (B) HepG2 cells are incubated with or without Compound C for 1 h, the cells are switched to medium D in the presence of vehicle, or AHI.
    CNE-2Z cells are treated with AZD8055 or Rapamycin with or without 1 T SMF for 3 d before they are harvested for Western blot.

    • Biologische Aktivität

    • Reinheit & Dokumentation

    • Verweise

    • Kundenbewertung

    Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant.

    mTOR

    0.1 nM (IC50, in HEK293 cells )

    Microbial Metabolite

     

    Autophagy

     

    Human Endogenous Metabolite

     

    In Vitro

    Rapamycin (12.5-100 nM; 24 hours) treatment exerts modest inhibitory effect on lung cancer cell proliferation in a dose-dependent manner in all cell lines (A549, SPC-A-1, 95D and NCI-H446 cells) tested, achieving about 30-40% reduction in cell proliferation at 100 nM vs. ~10% reduction at 12.5 nM.
    Lung cancer cell line 95D cells are exposed to Rapamycin (10 nM, 20 nM) and RP-56976 (1 nM, 10 nM) alone or in combination (Rapamycin 20 nM+ RP-56976 10 nM). After 24 hours exposure to Rapamycin or RP-56976 alone does not significantly alter the level of expression or phosphorylation of ERK1/2, whereas cells treated with the combination of Rapamycin with RP-56976 exhibit a marked reduction in the phosphorylation levels of ERK1/2.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Rapamycin Related Antibodies

    Cell Viability Assay

    Cell Line: Lung cancer cell lines A549, SPC-A-1, 95D and NCI-H446
    Concentration: 12.5 nM, 25 nM, 50 nM, 100 nM
    Incubation Time: 24 hours
    Result: Treatment exerted modest inhibitory effect on lung cancer cell proliferation in a dose-dependent manner in all cell lines.

    Western Blot Analysis

    Cell Line: 95D cells
    Concentration: 10 nM and 20 nM
    Incubation Time: 24 hours
    Result: Combination treatment with RP-56976 decreased phosphorylation of ERK.
    In Vivo

    Rapamycin (2.0 mg/kg; intraperitoneal injection; every other day; 28 days) alone has a moderate inhibitory effect. However, the combination of Metformin and Rapamycin exerts a significantly increased inhibition of tumor growth compared with the control group, the Rapamycin monotherapy group and the Metformin monotherapy group.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: 24 male nu/nu mice aged 4-5 week old (15-20 g)
    Dosage: 2.0 mg/kg
    Administration: Intraperitoneal injection; every other day; 28 days
    Result: Had a moderate inhibitory effect in monotherapy group. The combination with Metformin exerted a significantly increased inhibition of tumor growth.

    914.17

    Solid

    C51H79NO13

    53123-88-9

    O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O
    • Antibiotics
    • Disease Research
    • Anti-inflammation/Immunoregulatory
    • Antibiotics
    • Macrolide Antibiotics

    bacterium Streptomyces hygroscopicus

    Room temperature in continental US; may vary elsewhere.
    In Vitro: 

    DMSO : 125 mg/mL (136.74 mM; Need ultrasonic)

    Ethanol : 50 mg/mL (54.69 mM; Need ultrasonic)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.0939 mL 5.4694 mL 10.9389 mL
    5 mM 0.2188 mL 1.0939 mL 2.1878 mL
    10 mM 0.1094 mL 0.5469 mL 1.0939 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Add each solvent one by one:  10% EtOH    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.5 mg/mL (2.73 mM); Suspended solution

    • 2.

      Add each solvent one by one:  10% EtOH    90% (20% SBE-β-CD in saline)

      Solubility: 2.5 mg/mL (2.73 mM); Suspended solution; Need ultrasonic

    • 3.

      Add each solvent one by one:  10% EtOH    90% corn oil

      Solubility: ≥ 2.5 mg/mL (2.73 mM); Suspended solution

    • 4.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.08 mg/mL (2.28 mM); Clear solution

    • 5.

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

      Solubility: 2.08 mg/mL (2.28 mM); Suspended solution; Need ultrasonic

    • 6.

      Add each solvent one by one:  10% DMSO    90% corn oil

      Solubility: ≥ 2.08 mg/mL (2.28 mM); Clear solution

    *All of the co-solvents are available by MCE.

    • [1]. Edwards SR, et al. The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain. J Biol Chem, 2007, 282(18), 13395-13401.  [Content Brief]

      [2]. Rangaraju S, et al. Rapamycin activates autophagy and improves myelination in explant cultures from neuropathicmice. J Neurosci. 2010 Aug 25;30(34):11388-97.  [Content Brief]

      [3]. Niu H, et al. Rapamycin potentiates cytotoxicity by RP-56976 possibly through downregulation of Survivin in lung cancer cells. J Exp Clin Cancer Res. 2011 Mar 10;30:28.  [Content Brief]

      [4]. Zhang JW, et al. Metformin synergizes with rapamycin to inhibit the growth of pancreatic cancer in vitro and in vivo. Oncol Lett. 2018 Feb;15(2):1811-1816.  [Content Brief]

    • [1]. Edwards SR, et al. The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain. J Biol Chem, 2007, 282(18), 13395-13401.

      [2]. Rangaraju S, et al. Rapamycin activates autophagy and improves myelination in explant cultures from neuropathicmice. J Neurosci. 2010 Aug 25;30(34):11388-97.

      [3]. Niu H, et al. Rapamycin potentiates cytotoxicity by RP-56976 possibly through downregulation of Survivin in lung cancer cells. J Exp Clin Cancer Res. 2011 Mar 10;30:28.

      [4]. Zhang JW, et al. Metformin synergizes with rapamycin to inhibit the growth of pancreatic cancer in vitro and in vivo. Oncol Lett. 2018 Feb;15(2):1811-1816.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • PI3K/Akt/mTOR Immunology/Inflammation Autophagy Apoptosis Anti-infection Metabolic Enzyme/Protease
    • mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Sie könnten auch an folgenden Produkten interessiert sein:



    Katalog-Nummer
    Beschreibung
    Cond.
    Preis zzgl. MwSt.